NCT06201234View on ClinicalTrials.gov

Evaluating the Addition of Elacestrant (oral SERD) to Olaparib (PARP-inhibitor) in Patients with Advanced/metastatic HR+/HER2- Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 MutationBRCA2 Mutation
Interventions
DRUG

Olaparib + Elacestrant

Olaparib 600 mg orally daily and elacestrant 400 mg orally daily

DRUG

Olaparib

Olaparib 600 mg orally daily

Trial Locations (2)

60431

NOT_YET_RECRUITING

Agaplesion Frankfurter Diakonie Kliniken gGmbH, Frankfurt am Main

88212

RECRUITING

MVZ für Hämatologie und Onkologie Ravensburg GmbH Studienzentrum, Ravensburg

All Listed Sponsors
collaborator

Stemline Therapeutics, Inc.

INDUSTRY

lead

GBG Forschungs GmbH

OTHER